Compare OFIX & TOI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OFIX | TOI |
|---|---|---|
| Founded | 1987 | 2007 |
| Country | United States | United States |
| Employees | N/A | 641 |
| Industry | Medical/Dental Instruments | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 473.3M | 565.9M |
| IPO Year | 1998 | N/A |
| Metric | OFIX | TOI |
|---|---|---|
| Price | $11.32 | $5.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $17.25 | $6.67 |
| AVG Volume (30 Days) | 383.7K | ★ 2.2M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.39 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $822,312,000.00 | N/A |
| Revenue This Year | $6.13 | $30.15 |
| Revenue Next Year | $6.22 | $25.77 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.85 | N/A |
| 52 Week Low | $8.85 | $2.32 |
| 52 Week High | $16.99 | $6.67 |
| Indicator | OFIX | TOI |
|---|---|---|
| Relative Strength Index (RSI) | 53.87 | 43.73 |
| Support Level | $11.11 | $4.90 |
| Resistance Level | $12.40 | $5.63 |
| Average True Range (ATR) | 0.50 | 0.42 |
| MACD | -0.03 | -0.12 |
| Stochastic Oscillator | 34.88 | 2.11 |
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two reportable segments: Global Spine and Global Limb Reconstruction. The Global Spine segment offers bone growth therapies, spinal implants, biologics, and enabling technologies used in spinal procedures. The Global Limb Reconstruction segment provides products and solutions for limb deformity correction, limb lengthening, fracture management, and limb preservation, supported by digital technologies. It generates the majority of its revenue from the Global Spine segment.
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.